Polaryx Therapeutics, Inc. (PLYX) — SEC Filings
Polaryx Therapeutics, Inc. (PLYX) — 1 SEC filings. Latest: S-1 (Nov 21, 2025). Sentiment: mixed. Includes 1 S-1. Overall sentiment: mixed.
View Polaryx Therapeutics, Inc. on SEC EDGAR
Overview
Polaryx Therapeutics, Inc. (PLYX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-1 filed on Nov 21, 2025: Polaryx Therapeutics, Inc. (PLYX) is a clinical-stage biotechnology company focused on rare pediatric lysosomal storage disorders (LSDs), pursuing a direct listing on The Nasdaq Capital Market. The company's lead candidate, PLX-200 (gemfibrozil), an oral small molecule, is being advanced through a P
Sentiment Summary
Across 1 filings, the sentiment breakdown is: 1 mixed. The dominant filing sentiment for Polaryx Therapeutics, Inc. is mixed.
Filing Type Overview
Polaryx Therapeutics, Inc. (PLYX) has filed 1 S-1 with the SEC between Nov 2025.
Recent SEC Filings (1)
| Date | Form | Description | Risk |
|---|---|---|---|
| Nov 21, 2025 | S-1 | Polaryx Targets Nasdaq Listing, Advances PLX-200 for Rare LSDs | high |
Risk Profile
Risk Assessment: Of PLYX's 1 recent filings, 1 were flagged as high-risk, 0 as medium-risk, and 0 as low-risk. The overall risk profile suggests elevated risk that warrants close monitoring.
Key Executives
- Alex Yang
- Ryan A. Murr
- Melanie E. Neary
Industry Context
The rare pediatric lysosomal storage disorder market is characterized by high unmet medical needs and significant scientific innovation. Companies in this space often leverage orphan drug designations and expedited review pathways to accelerate development. The competitive landscape includes both established pharmaceutical companies and emerging biotechs, with a growing focus on genetic therapies and novel small molecules. Regulatory hurdles are substantial, but successful drug development can lead to significant market exclusivity and premium pricing.
Top Tags
Biotechnology (1) · Rare Diseases (1) · Lysosomal Storage Disorders (1) · Direct Listing (1) · Clinical Stage (1) · Orphan Drug (1) · Nasdaq (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Price per share | $0.29 | Issuance price for 24,970,062 shares in 2024 |
| Average price per share | $0.64 | Issuance price for 1,885,408 shares in September 2025 through filing date |
| Shares issued | 24,970,062 | Number of common shares issued to investors during 2024 |
| Expected trial initiation | 2026 | Expected initiation of PLX-200 Phase 2 SOTERIA basket trial in the first half of 2026 |
| Orphan Drug Designations | 3 | Number of ODDs granted to PLX-200 by the FDA |
| Fast Track Designation | 1 | Number of Fast Track designations granted to PLX-200 for CLN3 |
Frequently Asked Questions
What are the latest SEC filings for Polaryx Therapeutics, Inc. (PLYX)?
Polaryx Therapeutics, Inc. has 1 recent SEC filings from Nov 2025, including 1 S-1. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PLYX filings?
Across 1 filings, the sentiment breakdown is: 1 mixed. The dominant sentiment is mixed.
Where can I find Polaryx Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Polaryx Therapeutics, Inc. (PLYX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Polaryx Therapeutics, Inc.?
Financial highlights for Polaryx Therapeutics, Inc. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for PLYX?
The investment thesis for PLYX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Polaryx Therapeutics, Inc.?
Key executives identified across Polaryx Therapeutics, Inc.'s filings include Alex Yang, Ryan A. Murr, Melanie E. Neary.
What are the main risk factors for Polaryx Therapeutics, Inc. stock?
Of PLYX's 1 assessed filings, 1 were flagged high-risk, 0 medium-risk, and 0 low-risk.
What are recent predictions and forward guidance from Polaryx Therapeutics, Inc.?
Forward guidance and predictions for Polaryx Therapeutics, Inc. are extracted from SEC filings as they are enriched.